VivoSeq
Neurology

Parkinson

0

Pipeline Programs↗

7

Active Trials↗

6

Companies Involved↗

Parkinson is an early-stage landscape with 0 programs across 6 companies. The most active players are EMD Serono, UCB, Boehringer Ingelheim.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

27/100

Mech. Concentration

N/A

Completion Rate

90/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

EMD Serono logo

EMD Serono

0 programs

PreclinicalUCB logo

UCB

0 programs

PreclinicalBoehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalA

Agyany Pharma LTD

0 programs

PreclinicalM

Montiha Azeem

0 programs

PreclinicalN

Neuro Group XR Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

19

clinical trials

Completed9 · 47%
Recruiting4 · 21%
Not yet recruiting2 · 11%
Unknown status2 · 11%
Withdrawn1 · 5%
Active, not recruiting1 · 5%

Clinical Trials

Trial Activity

19 trials

Vinpocetine in Patients With Parkinsonian Disease
Recruiting·TTanta University·Phase 2/3·NCT07229664·60 enrolled
Evaluation of Long-term Safety in Parkinsonian Patients With Intracerebroventricular Administration of A-dopamine (Anaerobic Dopamine)
Recruiting·UUniversity Hospital, Lille·Phase 1/2·NCT07214285·1 enrolled
Development and Investigation of the Effectiveness of an External Stimulus-Supported Gait Training Mobile Application for Patients With Parkinson's Disease
Recruiting·EEge University·Preclinical·NCT07687979·52 enrolled
Adaptive vs Conventional Deep Brain Stimulation for Parkinson's Disease: A Multi-center Randomized Controlled Trial
Recruiting·BBeijing Pins Medical Co., Ltd·Preclinical·NCT07635823·60 enrolled
Plasticity of Motor Systems in Early Stage Parkinson's Disease
Active, not recruiting·UUniversity of Minnesota·N/A·NCT05286736·50 enrolled
Cilostazol in Parkinson's Disease
Not yet recruiting·—·Phase 2·NCT06612593·50 enrolled
Etoricoxib in Patients With Parkinsonian Disease
Not yet recruiting·—·Phase 2·NCT07370532·60 enrolled
Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia
Completed·EMD Serono logoEMD Serono·Phase 2·NCT00314288·360 enrolled
Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)
Completed·BBial - Portela C S.A.·Phase 3·NCT04978597·410 enrolled
Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management
Completed·UCB logoUCB·Phase 4·NCT03103919·40 enrolled
Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 3·NCT00601523·511 enrolled
Intermittent Oral Administration vs. Semi-continuous Intra-oral Administration of Levodopa/Carbidopa in Fluctuating Parkinsonian Patients
Completed·IIRCCS San Raffaele Roma·Phase 2·NCT02763137·18 enrolled
Evaluation of the Nonmotor Symptomatology of Parkinsonian Patients Treated With Two Strategies Related to Apomorphine Pump Therapy in French Hospitals
Completed·RRennes University Hospital·N/A·NCT03693872·43 enrolled
PET Scanning in Parkinson s Disease
Completed·National Institute of Mental Health (NIMH)·N/A·NCT00024622·502 enrolled
Virtual Reality Verses Conventional Physical Therapy in Parkinson's Disease Patients
Completed·—·Preclinical·NCT07359716·62 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)